JP2008050365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008050365A5 JP2008050365A5 JP2007276853A JP2007276853A JP2008050365A5 JP 2008050365 A5 JP2008050365 A5 JP 2008050365A5 JP 2007276853 A JP2007276853 A JP 2007276853A JP 2007276853 A JP2007276853 A JP 2007276853A JP 2008050365 A5 JP2008050365 A5 JP 2008050365A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 36
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 33
- 239000012453 solvate Substances 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 14
- 150000004677 hydrates Chemical class 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- -1 het 1 Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000036571 hydration Effects 0.000 claims 2
- 238000006703 hydration reaction Methods 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000027219 Deficiency disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010064948 Viral rhinitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 230000008369 airway response Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000005961 oxazepanyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04291187A EP1593679A1 (en) | 2004-05-07 | 2004-05-07 | 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands |
| GB0504564A GB0504564D0 (en) | 2005-03-04 | 2005-03-04 | New compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512541A Division JP4173191B2 (ja) | 2004-05-07 | 2005-04-19 | Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008050365A JP2008050365A (ja) | 2008-03-06 |
| JP2008050365A5 true JP2008050365A5 (https=) | 2008-10-30 |
Family
ID=34964551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512541A Expired - Fee Related JP4173191B2 (ja) | 2004-05-07 | 2005-04-19 | Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体 |
| JP2007276853A Withdrawn JP2008050365A (ja) | 2004-05-07 | 2007-10-24 | Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512541A Expired - Fee Related JP4173191B2 (ja) | 2004-05-07 | 2005-04-19 | Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体 |
Country Status (36)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| JP2007517056A (ja) | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| JP2006213674A (ja) * | 2005-02-07 | 2006-08-17 | Ube Ind Ltd | ４−ホルミルテトラヒドロピラン化合物の製法 |
| EP2455075B1 (en) | 2005-07-06 | 2018-06-20 | Sunovion Pharmaceuticals Inc. | Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine |
| WO2007045989A1 (en) * | 2005-10-20 | 2007-04-26 | Pfizer Limited | Pyridyl derivatives useful as h3 ligands |
| US20070203111A1 (en) * | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| NZ569608A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
| CN101421228B (zh) | 2006-03-31 | 2014-05-21 | 塞普拉柯公司 | 手性酰胺和胺的制备 |
| AR060404A1 (es) | 2006-04-11 | 2008-06-11 | Novartis Ag | Compuestos organicos utiles como inhibidores de dipeptidil-peptidasa iv |
| CN103382174A (zh) | 2006-06-23 | 2013-11-06 | 雅培制药有限公司 | 作为组胺h3受体调节物的环丙胺衍生物 |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US20130012485A1 (en) * | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CA2688493C (en) | 2007-05-31 | 2016-04-19 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| AU2011261375B2 (en) | 2010-06-04 | 2016-09-22 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| EA023375B1 (ru) * | 2011-10-26 | 2016-05-31 | Пфайзер Лимитед | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов |
| WO2014095534A1 (en) * | 2012-12-19 | 2014-06-26 | Basf Se | New substituted triazoles and imidazoles and their use as fungicides |
| LT3309150T (lt) * | 2013-01-09 | 2021-10-25 | Arena Pharmaceuticals, Inc. | (r)-3-(4'-(2-(2-metilpirolidin-1-il)etil)bifenil-4-il)propano rūgštis, kaip histamino h3 receptorių moduliatoriai, skirti kognityvinių sutrikimų gydymui |
| US9067914B1 (en) | 2013-12-10 | 2015-06-30 | Genzyme Corporation | Tropomyosin-related kinase (TRK) inhibitors |
| TWI696621B (zh) | 2014-12-18 | 2020-06-21 | 美商健臻公司 | 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物 |
| CN113336715B (zh) * | 2021-08-04 | 2021-11-23 | 山东海利尔化工有限公司 | 一种含二氧戊环的三唑类化合物及其中间体的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3024836A1 (de) * | 1980-07-01 | 1982-01-28 | A. Nattermann & Cie GmbH, 5000 Köln | (3-alkylamino-2-hydroxy-propoxy)-benzylnitrile, verfahren zu deren herstellung und diese als wirkstof enthaltende arzneimittel |
| DK368687A (da) * | 1986-11-21 | 1988-05-22 | Cheminova As | Aminoalkylerede hydroxyforbindelser og deres anvendelse som fungicider |
| BR0108088A (pt) * | 2000-07-13 | 2004-04-06 | Abbott Lab | Pirrolidinas 1,3-dissubstituìdas e 1,3,3-trissubstituìdas como ligandos receptores de histamina-3 e suas aplicações terapêuticas |
| CZ2003686A3 (cs) * | 2000-08-08 | 2003-08-13 | Ortho Mcneil Pharmaceutical, Inc. | Neimidazolové aryloxypiperidiny |
| JP2004532834A (ja) * | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
-
2005
- 2005-04-19 ES ES05718521T patent/ES2346665T3/es not_active Expired - Lifetime
- 2005-04-19 WO PCT/IB2005/001114 patent/WO2005108384A1/en not_active Ceased
- 2005-04-19 JP JP2007512541A patent/JP4173191B2/ja not_active Expired - Fee Related
- 2005-04-19 BR BRPI0510664A patent/BRPI0510664B8/pt active IP Right Grant
- 2005-04-19 CA CA2565852A patent/CA2565852C/en not_active Expired - Fee Related
- 2005-04-19 GE GEAP20059693A patent/GEP20094826B/en unknown
- 2005-04-19 NZ NZ550769A patent/NZ550769A/en not_active IP Right Cessation
- 2005-04-19 CN CN2005800146623A patent/CN1950351B/zh not_active Expired - Fee Related
- 2005-04-19 SI SI200531085T patent/SI1747210T1/sl unknown
- 2005-04-19 AU AU2005240846A patent/AU2005240846B2/en not_active Ceased
- 2005-04-19 DE DE602005022062T patent/DE602005022062D1/de not_active Expired - Lifetime
- 2005-04-19 KR KR1020067023284A patent/KR100843848B1/ko not_active Expired - Fee Related
- 2005-04-19 MX MXPA06012819A patent/MXPA06012819A/es not_active Application Discontinuation
- 2005-04-19 AT AT05718521T patent/ATE472540T1/de active
- 2005-04-19 HR HR20100469T patent/HRP20100469T1/hr unknown
- 2005-04-19 PT PT05718521T patent/PT1747210E/pt unknown
- 2005-04-19 EP EP05718521A patent/EP1747210B1/en not_active Expired - Lifetime
- 2005-04-19 DK DK05718521.7T patent/DK1747210T3/da active
- 2005-04-19 RS RSP-2010/0382A patent/RS51403B/sr unknown
- 2005-04-19 EA EA200601868A patent/EA011161B1/ru not_active IP Right Cessation
- 2005-04-19 PL PL05718521T patent/PL1747210T3/pl unknown
- 2005-04-19 AP AP2006003772A patent/AP2353A/xx active
- 2005-05-04 UY UY28883A patent/UY28883A1/es unknown
- 2005-05-04 PE PE2005000505A patent/PE20060237A1/es not_active Application Discontinuation
- 2005-05-04 NL NL1028968A patent/NL1028968C2/nl not_active IP Right Cessation
- 2005-05-05 AR ARP050101824A patent/AR048939A1/es unknown
- 2005-05-05 GT GT200500107A patent/GT200500107A/es unknown
- 2005-05-05 MY MYPI20052001A patent/MY144634A/en unknown
- 2005-05-06 TW TW096139294A patent/TW200815412A/zh unknown
- 2005-05-06 PA PA20058632201A patent/PA8632201A1/es unknown
- 2005-05-06 SV SV2005002107A patent/SV2006002107A/es unknown
- 2005-05-06 TW TW094114791A patent/TWI346549B/zh not_active IP Right Cessation
-
2006
- 2006-10-04 IL IL178433A patent/IL178433A/en active IP Right Grant
- 2006-11-06 CR CR8729A patent/CR8729A/es unknown
- 2006-11-07 MA MA29438A patent/MA28634B1/fr unknown
- 2006-11-08 EC EC2006006975A patent/ECSP066975A/es unknown
-
2007
- 2007-10-24 JP JP2007276853A patent/JP2008050365A/ja not_active Withdrawn
-
2010
- 2010-08-10 CY CY20101100747T patent/CY1110735T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008050365A5 (https=) | ||
| CA2565852C (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| JP4084410B2 (ja) | ヒスタミンｈ３受容体リガンドとして有用なテトラヒドロナフチリヂン誘導体 | |
| CN108463458B (zh) | ROR-γ的调节剂 | |
| CN112384500B (zh) | 免疫调节剂及其组合物和制备方法 | |
| AU2010277688B2 (en) | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | |
| JP2012502067A5 (https=) | ||
| US20130023532A1 (en) | Indazolyl-pyrimidines as kinase inhibitors | |
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| AR054127A1 (es) | Imidazoquinolinas como inhibidores de quinasa de lipido | |
| JP2010513283A5 (https=) | ||
| JP2015503529A5 (https=) | ||
| JP2016508505A (ja) | ピリダジノン−アミド誘導体 | |
| CN101094853A (zh) | 可用作蛋白激酶抑制剂的吡唑并[1,5－a]嘧啶 | |
| JP2013531055A5 (https=) | ||
| CN1835922B (zh) | 制备4-芳基-烟酰胺衍生物的方法 | |
| JP2017512786A5 (https=) | ||
| JP2019514956A (ja) | 置換イミダゾ［１，２−ｂ］ピリダジン、置換イミダゾ［１，５−ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 | |
| WO2012114268A1 (en) | Benzamide derivatives as p2x7 receptor antagonists | |
| JP2010527984A5 (https=) | ||
| CN111212833B (zh) | 苯基吡啶衍生物及包含其的药物组合物 | |
| JP2012524107A5 (https=) | ||
| CA2688326A1 (en) | Tetrahydroisoquinolin-1-one derivative or salt thereof | |
| JP2020503302A5 (https=) | ||
| JP4186518B2 (ja) | フェニルピリジン誘導体 |